The data are being presented at the Paediatric Rheumatology European Society Congress (PReS) 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
The first study, conducted in Italy, showed entanercept to be effective, with a good safety profile, in children under four years of age (an as yet unlicensed patient population for the treatment). Thirty-three patients under four years of age with unresponsive JIA (24 female, 9 male) were treated with etanercept for an average of 23 months.
After the first 6 months of treatment, 82% achieved the ACR Pedi 30* response and 48% achieved the ACR Pedi 70* response. There was a low rate of mild adverse events, whilst one patient temporarily suspended treatment following hospitalisation for an infection.
The third study, also from The Netherlands ABC-project, showed that a substantial 57% of non-responders to etanercept at three months (12 patients from 21 non-responders of a total of 179 JIA patients; average age of 5.8 years) who continued with the treatment eventually responded. The researchers in this study thereby suggest extending the use of etanercept in non-responding patients beyond the commonly recommended three-month therapy window to achieve higher response rates in JIA patients.
* The American College of Rheumatology (ACR) pediatric criteria assess patient response to a treatment. An ACR Pedi 30 response represents a >30% improvement in JIA signs and symptoms, such as the number of swollen joints with loss of motion, assessment of pain and level of disability. ACR Pedi 50 represents a >50% improvement, and ACR Pedi 70 represents a >70% improvement.
Further details on the three studies are outlined below:
1. Safety and efficacy of etanercept in a cohort of juvenile idiopathic arthritis (JIA) patients under four years of age. (OP-0137)
Thirty-three patients with unresponsive JIA under four years of age in a single centre were treated with etanercept for a mean of 23 months (range 6-86), with all receiving other concurrent drug treatments. Efficacy (using ACR Pediatric 30, 50 and 70 criteria for improvement) and safety end points were recorded at each hospital visit.
The ACR Pedi 30 response was reached by 82% (27) after 6 months and 85% (28) at the last observation. The ACR Pedi 50 response was reached by 76% (25) at 6 months and 85% (28) at the last follow-up, and the ACR Pedi 70 response was reached by 48% and 73% respectively.
Four patients (12%) developed mild adverse events: including one case of cytomegalovirus infection and three varicella zoster virus (VZV) infections. One patient experienced a serious adverse event and was hospitalised for a necrotising fasciitis during VZV infection. No cases of tuberculosis, opportunistic infections or malignancies were reported.
2. Major improvements in health-related quality of life during the use of etanercept in patients with refractory juvenile idiopathic arthritis. (THU0426)
In 53 JIA patients, who previously did not respond to other second-line drugs, data were collected to evaluate HRQoL during treatment with etanercept. HRQoL was measured by the Childhood Health Assessment Questionnaire (CHAQ), Child Health Questionnaire (CHQ) and Health Utilities Index mark 3 (HUI3) before start and after 3, 15 and 27 months. At the same time-points, information on JIA disease activity variables were also collected, including; physician's global assessment through the Visual Analogue Scale (VAS), number of active and limited joints and erythrocyte sedimentation rate. Linear mixed models were used to assess outcomes over time.Significant improvements in HRQoL were seen during the 27 month study period. The disease specific CHAQ, including the VAS pain and VAS well-being scores showed a significant improvement on all domains (p
Dr Femke H.M. Prince of the Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands, said: "JIA, the most common cause of chronic arthritis in children, frequently results in physical disabilities and chronic pain influencing daily life. The results for the Arthritis and Biologicals in Children project show impressive improvement on all domains of Health-Related Quality of Life impaired by JIA during treatment with etanercept. This indicates that these previously severely ill children, as well as their families, gain great benefits from this treatment. The results of our studies add to the bank of research on the role of etanercept in treating JIA patients of all subtypes who previously have not responded to other second-line drugs."
3. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. (FRI0478)
From 179 JIA patients in the ABC-register, with a minimal follow-up of 15 months, the clinical response was assessed using the American College of Rheumatology Paediatric 30 variables. Of the 34 patients who initially failed to meet these response criteria, 21 continued etanercept therapy and 12 patients reached a delayed response at 15 months of treatment. Overall, 7% of the 179 patients were delayed responders after 3 months of treatment and this was most likely in those with the oligoarticular, arthritis psoriatica and enthesitis related arthritis subtypes.
Dr Marieke H. Otten of the Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands, said: 'Biological agents are one of the last therapeutic options for JIA and have shown to be highly effective in refractory patients. Previous studies on etanercept have shown rapid improvements, but the optimal duration to evaluate effectiveness is still unknown. This study shows a delayed clinical response in a substantial proportion of the patients treated with etanercept. We advise, especially in patients with a partial response, to continue treatment to at least six months.'For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress press office on:
PReS is a non-profit organisation whose purpose is to promote the knowledge of paediatric rheumatic diseases, stimulate research in these fields, disseminate such knowledge at meetings and publications, and provide guidelines and best standards in clinical practice and training in paediatric rheumatology.
The society represents paediatric rheumatology in EU organisations (such as Union of European Medical Specialists).
This year's 16th PReS Congress will be a joint congress with the 10th European League against Rheumatism (EULAR) congress. It is being held in Copenhagen, Denmark 10-13 June 2009.
The official websites are http://www.pres2009.dk/ and http://www.eular.org/
Further reports about: > ACR > Arthritis > CHAQ > CHQ > EULAR > European League Against Rheumatism > Forum Life Science 2009 > HRQoL > HUI3 > Health > JIA > OP-0137 > PReS > Rheumatology > VAS > VZV > anti-TNF > erythrocyte sedimentation rate > functional impairment > inflamed joints > juvenile idiopathic arthritis > movement and dexterity > rheumatism > tumour necrosis factor
Study relating to materials testing Detecting damages in non-magnetic steel through magnetism
23.07.2018 | Technische Universität Kaiserslautern
Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur
What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...
The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.
Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...
08.08.2018 | Event News
27.07.2018 | Event News
25.07.2018 | Event News
14.08.2018 | Information Technology
14.08.2018 | Life Sciences
14.08.2018 | Life Sciences